The latest Investing Matters Podcast episode featuring Jeremy Skillington, CEO of Poolbeg Pharma has just been released. Listen here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksDukemount Capi. Regulatory News (DKE)

Share Price Information for Dukemount Capi. (DKE)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 0.031
Bid: 0.027
Ask: 0.035
Change: 0.00 (0.00%)
Spread: 0.008 (29.63%)
Open: 0.031
High: 0.031
Low: 0.031
Prev. Close: 0.031
DKE Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Notice of AGM

14 Dec 2023 09:56

RNS Number : 8372W
Dukemount Capital PLC
14 December 2023
 

14 December 2023

Dukemount Capital Plc

("Dukemount" or the "Company")

 Notice to shareholders for annual general meeting, further advance under existing funding agreement, settlement to achieve a reduction in existing debt and completion of Chesterfield Conversion of debt

The board of directors, Dukemount Capital Plc, a SPAC (as confirmed in the announcement of 12 September 2023), is pleased to confirm the following:

· A circular will be posted on Monday 18 December to hold the annual general meeting of the Company on 12 January 2024. The resolutions (the "Resolutions") at the annual general meeting will be to, inter alia, restructure the share capital of the Company given the current trading price being below the nominal value.

· Through extensive discussions with the existing noteholders (the "Investors") pursuant to the existing funding agreement (as detailed in the announcement of 11 October 2022) (the "Existing Funding"), the directors have executed a net advance of £40,000 to fund immediate capital requirements of the Company.

· The Investors have agreed an irrevocable conditional amendment to the Existing Funding as follows:

The existing debt (inclusive of the further £40,000 advance) will be reduced to £900,000 (being a decrease of over 20% of the accrued balances).

No interest or fees to accrue during the term (i.e. the outstanding balance is frozen).

All rights to receive warrants pursuant to the Existing Funding are released and waived.

24 month repayment term from the date of the amendment being effective

Upon completion of a reverse takeover, the Company may elect for either (a) the Existing Funding to be converted into equity at the relevant placing price for the RTO or (b) the Existing Funding will be repaid (i) 50% of the outstanding balance on completion, (ii) 25% - 13 months from completion and (iii) 25% - 24 months from completion.

The amendments are conditional on the passing of the Resolutions and the Chesterfield Conversion below.

 

· As previously announced, Chesterfield Capital Limited has undertaken to convert the existing £500,000 debt at 0.0065 per ordinary share in the Company (being 76,923,076 ordinary shares when calculated prior to the reorganisation as detailed in the Resolutions) (the "Chesterfield Conversion"). Chesterfield Capital Limited has issued a subscription which is only conditional on the passing of the Resolutions.

CEO Elect Paul Gazzard commented:

"The board of directors are working closely with its broker, Peterhouse Capital, to consider all capital raising opportunities and to review prospects with regards to an RTO. At present the Company has no proceedable RTO opportunities, but we continue to review those presented to the board and will continue to ensure the market is kept up-to-date on progress. The additional funding from the Investors ensures the Company is on track to finalise its annual report for the 30 September 2023 year end and intends to publish those within the required timetable. Further, the restructure of the Existing Funding and the Chesterfield Conversion simplifies considerably the historic liabilities of the Company, something which the board believes will have a positive impact on progressing a potential RTO. The circular for the annual general meeting will be posted next week."

For further information, please visit www.dukemountcapitalplc.com or contact:

 

Dukemount Capital Plc : Email info@dukemountplc.com

CEO: Paul Gazzard

Non-Executive Director: Geoffery Dart

 

Broker Enquiries:

Peterhouse Capital Limited Tel: +44 (0) 207 469 0930

Lucy Williams/Duncan Vasey

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NOATIBLTMTABMIJ
Date   Source Headline
18th Apr 20243:09 pmRNSResult of AGM
21st Mar 20247:00 amRNSNotice of AGM and a conditional subscription
8th Mar 20244:29 pmRNSTR-1: Standard form notification of major holdings
7th Mar 202410:51 amRNSUpdate on the Facility Agreement and TVR
5th Mar 202412:45 pmRNSHolding(s) in Company
4th Mar 20241:16 pmRNSCapitalisation of Loan, Issue of Equity & Warrants
26th Feb 202410:04 amRNSHolding(s) in Company
30th Jan 202412:09 pmRNSFinal Results
12th Jan 20242:13 pmRNSResult of AGM
14th Dec 20239:56 amRNSNotice of AGM
12th Sep 20237:44 amRNSProposed lifting of suspension and other updates
16th Jun 20237:00 amRNSHalf-year Report
9th Jun 202310:17 amRNSFinal Results
22nd Nov 20227:06 amRNSChange of Broker
1st Nov 20228:03 amRNSTemporary Suspension
28th Oct 20224:40 pmRNSSecond Price Monitoring Extn
28th Oct 20224:35 pmRNSPrice Monitoring Extension
28th Oct 20229:32 amRNSIssue of Equity
27th Oct 20224:41 pmRNSSecond Price Monitoring Extn
27th Oct 20224:36 pmRNSPrice Monitoring Extension
26th Oct 20229:32 amRNSIssue of Equity
20th Oct 20229:26 amRNSIssue of Equity
19th Oct 202212:33 pmRNSHolding(s) in Company
19th Oct 20227:00 amRNSHolding(s) in Company
13th Oct 20222:05 pmRNSSecond Price Monitoring Extn
13th Oct 20222:00 pmRNSPrice Monitoring Extension
13th Oct 202211:05 amRNSSecond Price Monitoring Extn
13th Oct 202211:00 amRNSPrice Monitoring Extension
12th Oct 20227:00 amRNSIssue of Equity
11th Oct 20227:00 amRNSFurther Funding and Funding Restructuring
5th Oct 20229:05 amRNSSecond Price Monitoring Extn
5th Oct 20229:00 amRNSPrice Monitoring Extension
5th Oct 20227:20 amRNSCompletion of sale
23rd Feb 20224:40 pmRNSSecond Price Monitoring Extn
23rd Feb 20224:35 pmRNSPrice Monitoring Extension
28th Jan 20221:43 pmRNSInterim Results
4th Jan 20224:36 pmRNSHolding(s) in Company
29th Oct 20212:16 pmRNSFinal Results
7th Oct 202110:08 amRNSChange of Broker
4th Oct 20217:19 amRNSCompletion of Purchase of Energy Generation Sites
27th Sep 202110:44 amRNSHolding(s) in Company
15th Sep 20217:32 amRNSCompletion of Gas Peaking Funding
17th Aug 202110:55 amRNSHolding(s) in Company
10th Aug 202110:03 amRNSUpdate Re Funding
19th Jul 20217:00 amRNSHolding(s) in Company
19th Jul 20217:00 amRNSHolding(s) in Company
15th Jul 202111:19 amRNSResult of GM
30th Jun 20212:06 pmRNSSecond Price Monitoring Extn
30th Jun 20212:00 pmRNSPrice Monitoring Extension
29th Jun 20213:42 pmRNSNotice of GM

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.